We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Intercept Draws Complete Response Letter for Liver Fibrosis Treatment
Intercept Draws Complete Response Letter for Liver Fibrosis Treatment
The FDA issued Intercept Pharmaceuticals a complete response letter for its investigational drug, obeticholic acid (OCA), for liver fibrosis due to nonalcoholic steatohepatitis (NASH).